Structure-Based Drug DesignRuthenium Metallodrugs

Dr. Farha Arshi

Synthetic & Computational Chemist

Advancing Metal-Based Anticancer Therapeutics Through Molecular Design

Computational ChemistryMedicinal ChemistryDFT ModellingMolecular Docking
Dr. Farha Arshi — Synthetic & Computational Chemist
Research →
About →

University of Lucknow, India

PhD, Chemistry · NAAC A++

Scroll

0+

Ru Complexes

0+

Publications

0+

Citations

0

H-Index

0

Conferences

0+

Years Research

About the Research

From Bench to Bits — A Two-Pronged Approach

Imagine designing a molecular key that fits a cancer-related protein target, then using computational chemistry to understand why it behaves the way it does.

During my PhD, I synthesised ten novel ruthenium complexes and investigated their electronic structure, reactivity, and protein-binding behaviour using Density Functional Theory (DFT) and molecular docking. By integrating experimental synthesis with computational analysis, I correlated structural features with chemical and biological properties, providing mechanistic insights that guided the interpretation of experimental results.

Read the full research story →

Research Approach

  • ⚗️Synthesise Ru(III) & half-sandwich Ru(II)–arene Schiff-base complexes
  • 🔬Confirm structures by NMR, X-ray diffraction (where applicable), FT-IR & UV-Vis
  • 💻Model electronic properties via DFT (GAUSSIAN)
  • 🎯Predict binding via molecular docking (AutoDock / Discovery Studio)
  • 📊Establish SAR from combined computational & biological data
Focus Areas

Research Domains

🧬

Ruthenium Metallodrugs

Designing Ru(III) and half-sandwich Ru(II)–arene complexes as next-generation anticancer and antimycobacterial agents with selectivity advantages over cisplatin.

Organometallic SynthesisNMR / X-ray DiffractionDNA Binding StudiesAnticancer Assays
💻

Computational Drug Design

Applying DFT, HOMO–LUMO analysis, MEP mapping, and molecular docking to rationalise reactivity and predict binding affinities.

GAUSSIAN (DFT)AutoDock / Discovery StudioHOMO–LUMO & MEPADME Prediction
⚗️

Structure–Activity Relationships

Correlating electronic structure, ligand substitution patterns, and molecular geometry with experimental biological activity to understand structure–activity relationships across a series of ruthenium complexes.

SAR AnalysisElectronic Descriptor AnalysisSubstituent Effect StudiesComputational–Experimental Correlation
🔬

Biological Evaluation

Collaborating on anticancer, antimycobacterial, antioxidant, and DNA-binding studies and integrating the experimental findings with computational analyses to support mechanistic interpretation.

MTT Anticancer AssayMIC AntimycobacterialDPPH AntioxidantDNA Binding Fluorescence
Scientific Process

Research Workflow

01

Molecular Design

Design Ru(III) and half-sandwich Ru(II)–arene Schiff-base complexes based on coordination chemistry principles and literature-guided ligand selection.

02

Synthesis

Multistep organometallic synthesis of Ru(III) and half-sandwich Ru(II)–arene Schiff-base complexes.

03

Characterisation

¹H/¹³C NMR · FT-IR · UV-Vis · Single-crystal X-ray (where applicable) · CHNS elemental analysis.

04

Computational Analysis

DFT geometry optimisation, HOMO–LUMO, MEP maps, and molecular docking in GAUSSIAN / AutoDock.

05

Biological Evaluation

Anticancer, antimycobacterial, antioxidant assays; DNA binding kinetics via fluorescence.

06

Structure–Activity Interpretation

SAR analysis correlates substituent effects with potency to guide the next synthetic cycle.